Bristol Myers Squibb Co (BMY) stock
BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 15/3032% below fair value
$59.56−1.79 (-2.92%)
Close on Nov 18, 2026Market cap $121.75BP/E 13.2Yield 4.18%
Bristol Myers Squibb operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Bristol Myers Squibb's operating cash flow for the twelve months ending Sep 30, 2026 was $10.65B, down 35.9% year over year. For fiscal 2025 it was $14.16B, down 6.8% from the year before. Over ten years it grew 21.0% a year on average. The highest annual figure on record is $16.21B in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.16B | -6.8% |
| FY2024 | Dec 31, 2024 | $15.19B | +9.6% |
| FY2023 | Dec 31, 2023 | $13.86B | +6.1% |
| FY2022 | Dec 31, 2022 | $13.07B | -19.4% |
| FY2021 | Dec 31, 2021 | $16.21B | +15.3% |
| FY2020 | Dec 31, 2020 | $14.05B | +71.2% |
| FY2019 | Dec 31, 2019 | $8.21B | +16.2% |
| FY2018 | Dec 31, 2018 | $7.07B | +34.0% |
| FY2017 | Dec 31, 2017 | $5.28B | +72.5% |
| FY2016 | Dec 31, 2016 | $3.06B | +45.3% |
| FY2015 | Dec 31, 2015 | $2.11B | -33.1% |
| FY2014 | Dec 31, 2014 | $3.15B | -11.2% |
| FY2013 | Dec 31, 2013 | $3.55B | -48.9% |
| FY2012 | Dec 31, 2012 | $6.94B | +43.4% |
| FY2011 | Dec 31, 2011 | $4.84B | +7.8% |
| FY2010 | Dec 31, 2010 | $4.49B | +10.5% |
| FY2009 | Dec 31, 2009 | $4.07B | +9.7% |
| FY2008 | Dec 31, 2008 | $3.71B | +17.6% |
| FY2007 | Dec 31, 2007 | $3.15B | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.18B | -33.8% |
| Q2 FY2026 | Jun 30, 2026 | $3.39B | -13.4% |
| Q1 FY2026 | Mar 31, 2026 | $1.10B | -43.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.97B | -55.5% |
| Q3 FY2025 | Sep 30, 2025 | $6.31B | +12.9% |
| Q2 FY2025 | Jun 30, 2025 | $3.92B | +68.4% |
| Q1 FY2025 | Mar 31, 2025 | $1.95B | -31.1% |
| Q4 FY2024 | Dec 31, 2024 | $4.44B | +4.4% |
| Q3 FY2024 | Sep 30, 2024 | $5.59B | +17.7% |
| Q2 FY2024 | Jun 30, 2024 | $2.33B | +23.3% |
| Q1 FY2024 | Mar 31, 2024 | $2.83B | -4.6% |
| Q4 FY2023 | Dec 31, 2023 | $4.25B | +28.6% |
| Q3 FY2023 | Sep 30, 2023 | $4.75B | +28.9% |
| Q2 FY2023 | Jun 30, 2023 | $1.89B | -16.5% |
| Q1 FY2023 | Mar 31, 2023 | $2.97B | -22.1% |
| Q4 FY2022 | Dec 31, 2022 | $3.31B | -18.5% |
| Q3 FY2022 | Sep 30, 2022 | $3.69B | -30.0% |
| Q2 FY2022 | Jun 30, 2022 | $2.26B | -26.1% |
| Q1 FY2022 | Mar 31, 2022 | $3.81B | -0.3% |
| Q4 FY2021 | Dec 31, 2021 | $4.06B | +20.9% |
| Q3 FY2021 | Sep 30, 2021 | $5.27B | +132.3% |
| Q2 FY2021 | Jun 30, 2021 | $3.06B | -31.9% |
| Q1 FY2021 | Mar 31, 2021 | $3.82B | -2.9% |
| Q4 FY2020 | Dec 31, 2020 | $3.36B | +53.8% |
| Q3 FY2020 | Sep 30, 2020 | $2.27B | -11.3% |
| Q2 FY2020 | Jun 30, 2020 | $4.49B | +115.7% |
| Q1 FY2020 | Mar 31, 2020 | $3.94B | +183.2% |
| Q4 FY2019 | Dec 31, 2019 | $2.18B | -38.6% |
| Q3 FY2019 | Sep 30, 2019 | $2.56B | +99.8% |
| Q2 FY2019 | Jun 30, 2019 | $2.08B | +97.1% |
| Q1 FY2019 | Mar 31, 2019 | $1.39B | +18.3% |
| Q4 FY2018 | Dec 31, 2018 | $3.56B | +218.3% |
| Q3 FY2018 | Sep 30, 2018 | $1.28B | -25.3% |
| Q2 FY2018 | Jun 30, 2018 | $1.06B | -33.3% |
| Q1 FY2018 | Mar 31, 2018 | $1.18B | +36.5% |
| Q4 FY2017 | Dec 31, 2017 | $1.12B | -22.6% |
| Q3 FY2017 | Sep 30, 2017 | $1.71B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.58B | – |
| Q1 FY2017 | Mar 31, 2017 | $861.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.44B | – |
See a number that looks wrong?